Streetbeat News

AZTR

Azitra, Inc.

https://azitrainc.com

Industry

Biotechnology

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

U.S. stocks traded lower with the S&P 500 falling around 100 points. AT&T shares rose 5% after Q2 earnings, despite missing revenue estimates. Pieris Pharmaceuticals surged 78% on a merger agreement, while Sangamo Therapeutics rose 47% after a successful trial. PROG Holdings gained 21% on strong earnings. Azitra, Nuwellis, and Lamb Weston saw significant declines due to various financial issues.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 6:37 pm

General Dynamics Corporation (NYSE:GD) shares fell 5.2% after reporting worse-than-expected Q2 EPS results despite revenue growth. Other notable stock movements include significant gains for NuZee, Inc. (NASDAQ:NUZE) and Dermata Therapeutics, Inc. (NASDAQ:DRMA), and declines for Azitra, Inc. (NYSE:AZTR) and Tesla, Inc. (NASDAQ:TSLA).

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 5:26 pm

Azitra Inc. (AMEX:AZTR) shares are crashing after the company announced a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share. The stock is down 74.8% to $1.25 following the announcement.

Portfolio Pulse from Erica Kollmann

July 24, 2024 | 4:44 pm

U.S. stocks traded lower with the Dow down 0.76%, NASDAQ down 2.89%, and S&P 500 down 1.75%. Tesla shares plunged over 11% after Q2 results, missing earnings estimates but beating revenue expectations. Pieris Pharmaceuticals, Sangamo Therapeutics, and PROG Holdings saw significant gains, while Azitra, Nuwellis, and Lamb Weston Holdings experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 4:30 pm

U.S. stocks traded lower with the Dow Jones dipping around 400 points. Alphabet Inc. (GOOG) posted better-than-expected earnings and sales results for its second quarter. NuZee, Inc. (NUZE) shares shot up 230%, while Azitra, Inc. (AZTR) shares dropped 75% after a public offering announcement. Vintage Wine Estates, Inc. (VWE) announced bankruptcy filing and voluntary delisting.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 2:17 pm

Azitra shares are trading lower following the announcement of a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 10:54 am

Enphase Energy shares rose 6.2% in pre-market trading despite missing Q2 revenue and earnings estimates. Other notable pre-market movers include Dermata Therapeutics, NuZee, Regencell Bioscience, Allarity Therapeutics, NewGenIvf Group, Perfect Moment, ENGlobal Corporation, 1847 Holdings, and Seagate Technology among gainers, while Azitra, Conn’s, Verastem, ATI Physical Therapy, Volato Group, Chijet Motor, AtlasClear Holdings, Wheels Up Experience, SFL Corporation, and Tesla saw declines.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 9:27 am

Azitra has announced a $10 million public offering of 6,665,000 common shares and Class A warrants at a price of $1.50 per share.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:08 am

U.S. stocks traded slightly higher with the Dow Jones gaining over 50 points. Coca-Cola reported strong Q2 results and raised its FY24 forecast. Azitra, Adial Pharmaceuticals, and Frequency Electronics saw significant stock price increases, while Jaguar Health, TransCode Therapeutics, and Cellectar Biosciences experienced sharp declines.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 6:32 pm

Comcast Corporation (NASDAQ:CMCSA) shares fell 6.1% after reporting worse-than-expected Q2 sales results. Other notable stock movements include Azitra, Inc. (NYSE:AZTR) jumping 529% due to a new patent, and Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) rising 148% after advancing a study. General Motors Company (NYSE:GM) fell 6.1% after delaying EV projects.

Portfolio Pulse from Avi Kapoor

July 23, 2024 | 5:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.